长期使用醋酸甲羟孕酮(DMPA)与骨矿物质密度(BMD)之间的关联一直存在争议,从新西兰的三项病例对照研究中可以看出,泰国,和英国。在目前的BMD病例对照研究中,一组67名5-15岁期间使用DMPA的中国女性与218名未使用任何类固醇激素的相同年龄范围的女性进行了比较.发现DMPA使用者的腰椎BMD(L2-4)显着降低(0.93g/cm2),股骨颈(0.69g/cm2),转子(0.59g/cm2),和沃德三角形(0.58g/cm2),与对照组相比,其相应的BMD值分别为1.03g/cm2、0.83g/cm2、0.71g/cm2和0.78g/cm2(p<0.001)。据估计,L2-4年的平均骨丢失百分比为1.1%,股骨颈为2.3%,转子中的2.4%,沃德三角形中的3.5%。发现L2-4中骨丢失的百分比随着年龄的增长而更加明显。这项研究提供的信息表明,在中国人群中使用DMPA>5年与骨丢失有关,需要一项前瞻性研究来证实这些数据,这与两个病例对照研究不同。
长期使用醋酸甲羟孕酮(DMPA)对骨密度的影响仍存在争议。本研究比较了从香港(中国)计划生育协会连续招募的67名长期(5年或更长时间)DMPA使用者的骨矿物质密度,以及从香港8个家庭保健服务诊所招募的218名年龄匹配的对照者的骨矿物质密度。平均年龄为42.8岁(范围,DMPA组34-46岁)和40.0岁(范围,34-46岁)。身体质量指数,钙摄入量,两组的吸烟情况相似。DMPA使用的中位持续时间为6年(范围,5-15年)。长期DMPA使用者的骨密度明显低于腰椎对照组(0.93vs.1.03克/平方米。cm),股骨颈(0.69vs.0.83克/平方米。cm),转子(0.59vs.0.71克/平方米。cm),和沃德的三角形(0.58vs.0.78克/平方米。cm)。随着年龄的增长,L2-4中骨丢失的百分比更加明显。对于每年的DMPA使用,骨矿物质密度的降低估计为0.011g/sq。L2-4中的厘米(1.1%),0.0193克/平方米。股骨颈厘米(2.3%),0.0169克/平方米。cm(2.4%)在转子,和0.0277克/平方米。沃德三角形中的厘米(3.5%)。
The association between long-term use of depot-medroxyprogesterone acetate (DMPA) and bone mineral density (BMD) has been controversial, as seen in three case-control
studies in New Zealand, Thailand, and the United Kingdom. In the present case-controlled study of BMD, a group of 67 Chinese women who had used DMPA from 5-15 years was compared with 218 women of the same age range who had not used any steroidal hormones. DMPA users were found to have a significantly lower BMD at lumbar vertebra (L2-4) (0.93 g/cm2), neck of femur (0.69 g/cm2), trochanter (0.59 g/cm2), and Ward\'s triangle (0.58 g/cm2), as compared with the control group, whose corresponding BMD values were 1.03 g/cm2, 0.83 g/cm2, 0.71 g/cm2, and 0.78 g/cm2, respectively (p < 0.001). The average percentage of bone loss per year was estimated to be 1.1% in L2-4, 2.3% in neck of femur, 2.4% in trochanter, and 3.5% in Ward\'s triangle. The percentage of bone loss in L2-4 was found to be more pronounced with age. This study provided information that the use of DMPA in a Chinese group for > 5 years in associated with bone loss, and a prospective study is needed to confirm these data, which are different from two case-control
studies.
The effect of long-term use of depot medroxyprogesterone acetate (DMPA) on bone mineral density remains controversial. The present study compared bone mineral densities in 67 long-term (5 years or more) DMPA users recruited consecutively from the Hong Kong (
China) Family Planning Association with those in 218 age-matched controls recruited from 8 family health service clinics in Hong Kong. Mean age was 42.8 years (range, 34-46 years) in the DMPA group and 40.0 years (range, 34-46 years) among controls. Body mass index, calcium intake, and smoking were similar in both groups. The median duration of DMPA use was 6 years (range, 5-15 years). Long-term DMPA users had significantly lower bone mineral densities than controls at the lumbar vertebra (0.93 vs. 1.03 g/sq. cm), neck of femur (0.69 vs. 0.83 g/sq. cm), trochanter (0.59 vs. 0.71 g/sq. cm), and Ward\'s triangle (0.58 vs. 0.78 g/sq. cm). The percentage of bone loss in L2-4 was more pronounced with increasing age. For each year of DMPA use, the decrease in bone mineral density was estimated to be 0.011 g/sq. cm (1.1%) in L2-4, 0.0193 g/sq. cm (2.3%) in the neck of femur, 0.0169 g/sq. cm (2.4%) in the trochanter, and 0.0277 g/sq. cm (3.5%) in Ward\'s triangle.